Apelin: an antithrombotic factor that inhibits platelet function

Blood

Volumn 127, Issue 7, 2016, Pages 908-920

  Adam, Fŕederic ^a   Khatib, Abdel Majid ^b   Lopez, Jose Javier ^a   Vatier, Camille ^a,c   Turpin, Sabrina ^a   Muscat, Adeline ^a,c   Soulet, Fabienne ^b   Aries, Anne ^a   Jardin, Isaac ^d   Bobe, Regis ^a   Stepanian, Alain ^a,e,f   De Prost, Dominique ^a,f,g   Dray, Ćedric ^a,h   Rosado, Juan Antonio ^d   Valet, Philippe ^a,h   Feve, Bruno ^a,c,i   Siegfried, Geraldine ^b  

^a INSERM   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d UNIVERSITY OF EXTREMADURA   (Spain)

^e HÔPITAL LARIBOISIÈRE   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^h Université de Toulouse   (France)

ⁱ HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; APELIN; APELIN 13; APELIN 36; APELIN RECEPTOR; COLLAGEN; CYCLIC AMP; CYCLIC GMP; THROMBIN; THROMBOXANE A2; UNCLASSIFIED DRUG; ADIPOCYTOKINE; APLN PROTEIN, HUMAN; APLN PROTEIN, MOUSE; APLNR PROTEIN, HUMAN; APLNR PROTEIN, MOUSE; G PROTEIN COUPLED RECEPTOR; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING; BLEEDING TIME; BLOOD CLOTTING; CALCIUM MOBILIZATION; CONTROLLED STUDY; ENZYME IMMUNOASSAY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE RELEASE REACTION; THROMBOSIS; ANIMAL; CHEMICALLY INDUCED; GENETICS; KNOCKOUT MOUSE; METABOLISM; SIGNAL TRANSDUCTION; THROMBOCYTE;

ADIPOKINES; ANIMALS; BLOOD PLATELETS; HEMORRHAGE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, KNOCKOUT; PLATELET ADHESIVENESS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; THROMBIN; THROMBOSIS; THROMBOXANE A2;

EID: 84959419173     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-05-578781     Document Type: Article

References (49)

1. Smith JN, Negrelli JM, Manek MB, Hawes EM, Viera AJ. Diagnosis and management of acute coronary syndrome: an evidence-based update. J Am Board Fam Med. 2015;28(2): 283-293.
2. Franchi F, Angiolillo DJ. Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol. 2015;12(1):30-47.
3. Gurbel PA, Tantry US. Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives. JACC Heart Fail. 2014;2(1):1-14.
4. Projahn D, Koenen RR. Platelets: key players in vascular inflammation. J Leukoc Biol. 2012;92(6): 1167-1175.
5. Pitkin SL, Maguire JJ, Bonner TI, Davenport AP. International Union of Basic and Clinical Pharmacology. LXXIV. Apelin receptor nomenclature, distribution, pharmacology, and function. Pharmacol Rev. 2010;62(3): 331-342.
6. Pitkin SL, Maguire JJ, Kuc RE, Davenport AP. Modulation of the apelin/APJ system in heart failure and atherosclerosis in man. Br J Pharmacol. 2010;160(7):1785-1795.
7. Peltonen T, N¨apankangas J, Vuolteenaho O, et al. Apelin and its receptor APJ in human aortic valve stenosis. J Heart Valve Dis. 2009; 18(6):644-652.
8. Kuklinska AM, Sobkowicz B, Sawicki R, et al. Apelin: a novel marker for the patients with first ST-elevation myocardialinfarction. Heart Vessels. 2010;25(5):363-367.
9. Li Z, Bai Y, Hu J. Reduced apelin levels in stable angina. Intern Med. 2008;47(22): 1951-1955.
10. Weir RA, Chong KS, Dalzell JR, et al. Plasma apelin concentration is depressed following acute myocardial infarction in man. Eur J Heart Fail. 2009;11(6):551-558.
11. Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun. 1998;251(2): 471-476.
12. O'Dowd BF, Heiber M, Chan A, et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene. 1993;136(1-2): 355-360.
13. Kawamata Y, Habata Y, Fukusumi S, et al. Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta. 2001;1538(2-3):162-171.
14. Azizi M, Iturrioz X, Blanchard A, et al. Reciprocal regulation of plasma apelin and vasopressin by osmotic stimuli. J Am Soc Nephrol. 2008;19(5): 1015-1024.
15. De Mota N, Reaux-Le Goazigo A, El Messari S, et al. Apelin, a potent diuretic neuropeptide counteracting vasopressin actions through inhibition of vasopressin neuron activity and vasopressin release. Proc Natl Acad Sci USA. 2004;101(28):10464-10469.
16. Miettinen KH, Magga J, Vuolteenaho O, et al. Utility of plasma apelin and other indices of cardiac dysfunction in the clinical assessment of patients with dilated cardiomyopathy. Regul Pept. 2007;140(3):178-184.
17. Hosoya M, Kawamata Y, Fukusumi S, et al. Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem. 2000; 275(28):21061-21067.
18. Kuba K, Zhang L, Imai Y, et al. Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload. Circ Res. 2007;101(4):e32-e42.
19. Roger S, Pawlowski M, Habib A, Jandrot-Perrus M, Rosa JP, Bryckaert M. Costimulation of the Gi-coupled ADP receptor and the Gq-coupled TXA2 receptor is required for ERK2 activation in collagen-induced platelet aggregation. FEBS Lett. 2004;556(1-3):227-235.
20. Adam F, Kauskot A, Nurden P, et al. Platelet JNK1 is involved in secretion and thrombus formation. Blood. 2010;115(20): 4083-4092.
21. Denis C, Methia N, Frenette PS, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci USA. 1998;95(16):9524-9529.
22. Cosemans JM, Iserbyt BF, Deckmyn H, Heemskerk JW. Multiple ways to switch platelet integrins on and off. J Thromb Haemost. 2008; 6(8):1253-1261.
23. Lee DK, Saldivia VR, Nguyen T, Cheng R, George SR, O'Dowd BF. Modification of the terminal residue of apelin-13 antagonizes its hypotensive action. Endocrinology. 2005;146(1): 231-236.
24. Macaluso NJ, Pitkin SL, Maguire JJ, Davenport AP, Glen RC. Discovery of a competitive apelin receptor (APJ) antagonist. ChemMedChem. 2011;6(6):1017-1023.
25. McNamara CR, Degterev A. Small-molecule inhibitors of the PI3K signaling network. Future Med Chem. 2011;3(5):549-565.
26. von Appen F, Ullrich V, Brune B. Wortmannin interferes with thrombin-evoked secondary calcium redistribution in human platelets. Cell Signal. 1997;9(7):513-517.
27. Haslam RJ, Dickinson NT, Jang EK. Cyclic nucleotides and phosphodiesterases in platelets. Thromb Haemost. 1999;82(2): 412-423.
28. Wilson LS, Elbatarny HS, Crawley SW, Bennett BM, Maurice DH. Compartmentation and compartment-specific regulation of PDE5 by protein kinase G allows selective cGMPmediated regulation of platelet functions. Proc Natl Acad Sci USA. 2008;105(36): 13650-13655.
29. Maree AO, Fitzgerald DJ. Variable platelet response to aspirin and clopidogrel in atherothrombotic disease. Circulation. 2007; 115(16):2196-2207.
30. Angiolillo DJ, Capodanno D, Goto S. Platelet thrombin receptor antagonism and atherothrombosis. Eur Heart J. 2010;31(1): 17-28.
31. Scamuffa N, Calvo F, Chr etien M, Seidah NG, Khatib AM. Proprotein convertases: lessons from knockouts. FASEB J. 2006;20(12): 1954-1963.
32. Brass LF, Manning DR, Cichowski K, Abrams CS. Signaling through G proteins in platelets: to the integrins and beyond. Thromb Haemost. 1997; 78(1):581-589.
33. Trumel C, Payrastre B, Plantavid M, et al. A key role of adenosine diphosphate in the irreversible platelet aggregation induced by the PAR1- Activating peptide through the late activation of phosphoinositide 3-kinase. Blood. 1999;94(12): 4156-4165.
34. Charles CJ, Rademaker MT, Richards AM. Apelin-13 induces a biphasic haemodynamic response and hormonal activation in normal conscious sheep. J Endocrinol. 2006;189(3): 701-710.
35. Visser YP, Walther FJ, Laghmani el H, Laarse Av, Wagenaar GT. Apelin attenuates hyperoxic lung and heart injury in neonatal rats. Am J Respir Crit Care Med. 2010;182(10): 1239-1250.
36. Pang H, Han B, Yu T, Zong Z. Effect of apelin on the cardiac hemodynamics in hypertensive rats with heart failure. Int J Mol Med. 2014;34(3): 756-764.
37. Guo L, Li Q, Wang W, et al. Apelin inhibits insulin secretion in pancreatic beta-cells by activation of PI3-kinase-phosphodiesterase 3B. Endocr Res. 2009;34(4):142-154.
38. Zhang G, Xiang B, Dong A, et al. Biphasic roles for soluble guanylyl cyclase (sGC) in platelet activation. Blood. 2011;118(13): 3670-3679.
39. Li Z, Xi X, Gu M, et al; Li Z1. A stimulatory role for cGMP-dependent protein kinase in platelet activation. Cell. 2003;112(1):77-86.
40. Tatemoto K, Takayama K, Zou MX, et al. The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept. 2001;99(2-3):87-92.
41. Roger S, Paysant J, Badier-Commander C, Cordi A, Verbeuren TJ, F el etou M. Anti-aggregating effect of BAY 58-2667, an activator of soluble guanylyl cyclase. Vascul Pharmacol. 2010; 53(5-6):281-287.
42. Maxwell MJ, Westein E, Nesbitt WS, Giuliano S, Dopheide SM, Jackson SP. Identification of a 2-stage platelet aggregation process mediating shear-dependent thrombus formation. Blood. 2007;109(2):566-576.
43. Stalker TJ, Traxler EA, Wu J, et al. Hierarchical organization in the hemostatic response and its relationship to the platelet-signaling network. Blood. 2013;121(10):1875-1885.
44. Davi G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357(24): 2482-2494.
45. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111(25):3481-3488.
46. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel inaddition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345(7):494-502.
47. Serebruany VL, Kogushi M, Dastros-Pitei D, Flather M, Bhatt DL. The in-vitro effects of E5555, a protease-activated receptor (PAR)-1 antagonist, on platelet biomarkers in healthy volunteers and patients with coronary artery disease. Thromb Haemost. 2009;102(1): 111-119.
48. Chackalamannil S, Wang Y, Greenlee WJ, et al. Discovery of a novel, orally active himbacinebased thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem. 2008;51(11):3061-3064.
49. Becker RC, Moliterno DJ, Jennings LK, et al; TRA-PCI Investigators. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet. 2009;373(9667): 919-928.